Description

Psychopharmacology 2014
Engage the experts. Get your questions answered.

 

Broad trends are changing the mental health care landscape. New diagnostic criteria, shifts toward patient-centered care models, new therapies, evolving relicensure requirements, and much more. It's more important than ever to find education that not only covers all these topics, but is also innovative, engaging, and empowers you to reach improved outcomes.

That's the kind of education you'll find at the 38th Annual Psychopharmacology Conference. It provides psychiatrists, primary care and family practice physicians, nursing professionals, and other mental health professionals with all the tools you need to optimize your care for patients with psychiatric conditions.

  • Engage more than 30 renowned clinician-researchers during interactive sessions
  • Get your questions answered and translate enhanced knowledge into optimal patient care
  • Find content on the entire spectrum of psychiatric disorders: Anxiety, ADHD, bipolar disorder, depression, eating disorders, OCD, psychosis, PTSD, substance abuse, and more
  • Hear innovative research on neurotherapeutics, managing side effects, neuroimaging for addiction, drug interactions, TMS and novel stimulation, women's health, psychopharmacology for sleep disorders, and more
  • Solve the mystery of Maintenance of Certification (MOC) requirements and develop a plan to maximize your learning experience

 

Target Audience

This program is intended for: Psychiatrists, psychologists, general and family practice physicians, psychiatric nurses, physician assistants, nurse practitioners, residents and fellows, clinical social workers.

Learning Objectives

At the end of this educational activity, participants should be able to:

  • Identify rational, evidence-based pharmacologic and non-pharmacologic therapies for patients with unipolar, bipolar, treatment-resistant, and post-partum depression.
  • Assess obstacles to maintenance of long-term recovery and the liability issues associated with psychopharmacology.
  • Discuss diagnostic and evidenced-based treatment strategies for pediatric onset mood disorders.
  • Compare the neurobiology and evidence-based treatment approaches to addiction, anxiety, schizophrenia, and mood disorders.
  • Review the course and treatment of psychiatric disorders during pregnancy and menopause.
  • Recognize psychosocial issues and evidence-based treatment modalities for eating and sleep disorders.
  • Analyze drug interactions and the pharmacotherapy of adult ADHD and geriatric disorders.

Pricing

MDs/Doctoral-Level Professionals
Register on or before August 15, 2014: $849.00
Register after August 15, 2014: $899.00

Other Professionals or Trainees
Register on or before August 15, 2014: $599.00
Register after August 15, 2014: $649.00

Optional MOC Part 4 Event
(Saturday evening, includes dinner): $150.00 

Cancellation Policy

A $100.00 administrative fee will be deducted for cancellations made prior to October 10, 2014. Cancellation/refund requests must be received in writing no later than October 10, 2014. No refunds or credits will be made thereafter.

Accommodations

A limited number of rooms have been reserved at The Westin Copley Place at a discounted rate of $308.00 per night (plus state and local taxes) and are available on a first-come, first-served basis until October 3, 2014.

Click here to reserve a hotel room.

To reserve by phone, please call The Westin at 617-262-9600 (local) or 888-627-7216 (international) and specify that you are attending the "MGH Psychopharmacology" conference. 

Day Of

Reminder: Breakfast and two coffee breaks are provided. Lunch and dinner are not provided during this event, please make your own arrangements during the lunch and dinner hours.

Early Registration: If you are checking in to the Westin Copley Place on Thursday, October 23, you can pick up your meeting materials during Early Registration, which takes place from 4:00pm-7:00pm on the 3rd floor. Early Registration is highly recommended as it allows you to avoid the rush during Regular Registration on Friday morning.

Regular Registration: Opens at 7:00am on Friday, October 24, in the America Ballroom Foyer on the 4th floor outside the America Ballroom. Please check in early enough so you allow time to find a seat, as the conference begins promptly at 8:00am.

Parking: Parking at the Westin costs $38 for up to 8 hours, $51 for over 8 hours, and $51 for overnight. The Copley Place, Prudential Center, and Dartmouth Street parking garages, all nearby within 1-2 blocks of the hotel, range from $30-$36 for 10 hours and from $34-$39 for 24 hours.

MOC Module: All attendees are pre-registered at no cost for a companion online Maintenance of Certification (MOC) module. Any attendee may complete this module, although only physicians are eligible to receive CME credit. The module will be open for participation after the conference begins. The program materials folder you receive at the Registration Desk will contain more information.

Subway: The Westin Copley Place is nearby the Copley and Back Bay stations. View subway map and schedule.

Questions: Please contact us at (866) 644-7792 or email us at mghcme@partners.org.

Agenda

FRIDAY, OCTOBER 24, 2014
7:00–8:00 am Registration & Continental Breakfast
8:00–8:15 am Welcoming Remarks
Maurizio Fava, MD
8:15–8:35 am Introduction & Overview
Jerrold F. Rosenbaum, MD and Maurizio Fava, MD
  Module Topic – Mood Disorders
8:35–9:20 am Bipolar Depression
Andrew A. Nierenberg, MD
9:20–10:05 am Bipolar Long Term Management
Roy H. Perlis, MD, MSc
10:05–10:20 am Coffee Break
10:20–11:05 am Treatment Resistant Depression
Maurizio Fava, MD
11:05–12:05 pm Round Table Discussion
Moderator: Jerrold F. Rosenbaum, MD
Panelists: Andrew A. Nierenberg, MD; Roy H. Perlis, MD, MSc; Maurizio Fava, MD
12:05–1:05 pm Lunch (on your own)
  Module Topic – Anxiety/OCD
1:05–1:50 pm OCD
Michael A. Jenike, MD
1:50–2:35 pm PTSD
Naomi M. Simon, MD, MSc
2:35–3:20 pm Social Anxiety
Naomi M. Simon, MD, MSc
3:20–3:35 pm Coffee Break
3:35–4:20 pm OCD Spectrum Disorders
Lisa M. Zakhary, MD, PhD
4:20–5:05 pm Round Table Discussion
Moderator: Michael A. Jenike, MD
Panelists: Naomi M. Simon, MD, MSc; Lisa M. Zakhary, MD, PhD
5:05–6:15 pm Dinner (on your own)
6:15–7:15 pm
7:15–8:15 pm
Evening Seminars
***Begin at 6:15 pm and repeat at 7:15 pm – pick two.***
1.  Natural Medications for Psychiatric Disorders
David Mischoulon, MD, PhD
2.  Psychiatry in the Age of Health Care Reform: Challenges, Opportunities, and How to Make the Most of Them
Joy B. Rosen, MS; Jonathan E. Alpert, MD, PhD; Jeffrey B. Weilburg, MD; Trina E. Chang, MD, MPH; Christina M. Stone, RN, PMHCNS-BC
 3.  The Neurobiology of Addiction
A. Eden Evins, MD, MPH
 4.  Psychopharmacology of Sleep Disorders
John W. Winkelman, MD, PhD
 5a.
The Neurobiology of Mood and Psychotic Disorders
***Begins at 6:15 pm and does not repeat.***
Dost Öngür, MD, PhD
5b. Suicide
***Begins at 7:15 pm and does not repeat.***
Theodore A. Stern, MD
 6.  Cognitive-Behavioral Therapy to Augment Psychopharmalogical Therapy
Michael W. Otto, PhD

 

SATURDAY, OCTOBER 25, 2014

7:00–8:00 am

Maintenance of Certification: Where Do I Go From Here?

Tristan Gorrindo, MD
***This session is optional. All attendees are welcome.***

Continental Breakafst will be served.

8:00–8:10 am Main Program Welcoming Remarks
Tristan Gorrindo, MD
  Module Topic – Psychosis
8:10–8:55 am

First-Episode Psychosis and Schizophrenia
Oliver Freudenreich, MD, FAPM

8:55–9:30 am

Management of Side-Effects of Antipsychotics
David C. Henderson, MD

9:30–9:45 am Coffee Break
9:45–10:30 am

Drug Interactions
Jonathan E. Alpert, MD, PhD

10:30–11:30 am

Round Table Discussion
Moderator: Jonathan E. Alpert, MD, PhD
Panelists: Oliver Freudenreich, MD, FAPM; David C. Henderson, MD

11:30–12:30 pm Lunch Break 
 

Module Topic – New Therapies

12:30–1:30 pm

Stimulation and/or Surgical Approaches to Psychiatric Illness
Darin D. Dougherty, MD, MSc

1:30–2:30 pm New Treatments for Bipolar
Roy H. Perlis, MD, MSc
2:30–3:30 pm

New Treatments for Depression
George I. Papakostas, MD

3:30–4:30 pm

New Antipsychotics
David C. Henderson, MD

4:30–5:15 pm

Roundtable Discussion
Moderator: David C. Henderson, MD
Panelists: Darin D. Dougherty, MD, MSc; Roy H. Perlis, MD, MSc; George I. Papakostas, MD

5:15–6:15 pm

Dinner (on your own)

6:30–7:30 pm

Evening Seminars
***Begin at 6:30 pm and do not repeat – pick one.***
1. 

Violence and Risk Assessment in Clinical Practice
Ronald Schouten, MD, JD; FBI Supervisory Special Agent Robert C. Lewis

2. 

Maintenence of Certification Part 4: Performance in Practice
Tristan Gorrindo, MD
***This a ticketed event, dinner served.***

• Provides credits for ABPN MOC Part 4 requirements
• Requires some preparation in advance

 

SUNDAY, OCTOBER 26, 2014

7:00–8:00 am Continental Breakfast
8:00–8:10 am Welcoming Remarks & Review 
Tristan Gorrindo, MD
  Module Topic – Mood Disorders
8:10–9:10 am

Tobacco and Cocaine
A. Eden Evins, MD, MPH

9:10–10:10 am

Alcohol and Opiates
A. Edin Evins, MD, MPH

10:10–10:25 am Coffee Break
  Module Topic – Women’s Health
10:25–11:25 am

Pregnancy
Lee S. Cohen, MD

11:25–12:25 pm

Post-Partum Mood Disorders
Marlene P. Freeman, MD

12:25–1:25 pm Lunch (on your own)
  Module Topic – Across the Lifespan
1:25–2:10 pm

Pediatric Bipolar Disorder and Mood Disorders
Janet Wozniak, MD

2:10–3:05 pm

ADHD
Thomas J. Spencer, MD

3:05–3:50 pm

Eating Disorders
Emily K. Gray, MD

3:50–4:30 pm

Geriatrics
James M. Ellison, MD, MPH

4:30 pm

Adjourn

Maintenance of Certification (MOC)

We've heard from many attendees and colleagues across the country that understanding Maintenance of Certification (MOC) requirement is a major concern for busy clinicians. This year we've added a special focus on helping you understand MOC requirements and maximize your learning experience as you track your progress and complete the required steps in meeting your MOC goals.

Participate in each of the following MOC-related activities during our conference in 2014:

  • A Saturday morning session entitled "Maintenance of Certification: Where Do I Go From Here?", led by Tristan Gorrindo, MD, Director of Postgraduate Medical Education, Massachusetts General Hospital, that reviews at a high-level the various MOC requirements you face and the parameters and timelines you have to follow to complete them.
  • A Saturday evening ticketed event entitled "MOC Part 4: Performance in Practice" which is a component of MOC that is a quality improvement program designed to improve practice over the 10-year MOC cycle. Each PIP unit consists of chart reviews, peer reviews, and patient reviews. For more information about this module, see "MOC PIP Clinical Module". 
  • All registrants get free access to an ABPN-approved online MOC self-assessment module. We'll automatically register you for this free module and provide instructions during the conference how to access it.

MOC PIP Clinical Module

MOC Part 4: Performance in Practice Event 
Cost (Saturday evening ticketed event, includes dinner): $150.00
***Registration must be received by September 15, 2014.***

To add value to your educational experience, the MGH Psychiatry Academy is offering this special module for psychiatrists who need to meet the American Board of Psychiatry and Neurology (ABPN) Part 4 performance in practice (PIP) requirement for Maintenance of Certification (MOC). This PIP module is designed to assess your clinical performance in recognizing and treating fatigue in patients with major depressive disorder, and then provide educational activities aimed at enhancing your knowledge-base and clinical skills.

Performance in practice (PIP) activities are required as part of ABPN Maintenance of Certification (MOC) requirements. PIP is a quality improvement activity for physicians to assess their current practice patterns, compare those practice patterns to a set of best-practices, participate in educational activities to improve their practice, and then re-evaluate their practice following the educational interventions.

How this module works:
The entire activity takes 12-24 months to complete and consists of three stages.

Stage A – Initial Assessment
Prior to the live Psychopharmacology course in October, you will collect and enter data from five of your patients with a primary diagnosis of major depression. Stage A must be completed by October 6, 2014 so that we can prepare feedback regarding your performance in evaluating and treating these patients.

Stage B – Educational Interventions
On Saturday evening during the live Psychopharmacology course, David Mischoulon, MD, PhD and Tristan Gorrindo, MD will present a workshop on "Medication-Induced Apathy and Fatigue: Avoiding Iatrogenesis." The registration fee of $150.00 for this module includes dinner. After the course, you will be provided with optional online educational content including an online simulation, links to published papers, rating scales and other tools that you can use with your patients. Complete educational interventions by December 15, 2014.

Stage C – Follow-Up Assessment
You will again collect and enter data from 5 of your patients with a primary diagnosis of major depression. These patients must have been evaluated after completion of Stage B. You will receive feedback regarding your performance in evaluating and treating these patients. Complete Stage C within 24 months of completing Stage B. 
***Your participation in this activity will be reported to the ABPN within 6 weeks of completion. Your individual answers will not be reported to the Board.***

How to register:
This module is only available to psychiatrists registering for the Psychopharmacology conference.

  1. Click the orange Register button at the top right of your screen and follow the prompts.
  2. You will be taken to the payment site for the live Psychopharmacology 2014 course, where you will have the option to add the MOC 4 module to your purchase.

 Undecided?

We recommend that you sign up for the module as soon as you decide to participate. However, if you do not choose to register for the module during the purchase process, you will still have the opportunity to register separately. Call us at 866-644-7792 or email us at mghcme@partners.org for more information.

Faculty

  • Associate Chief of Psychiatry for Clinical Services
    Director, Depression Clinical and Research Program
    Massachusetts General Hospital
    Joyce R. Tedlow Associate Professor of Psychiatry
    Harvard Medical School
  • Director of Community-Based Studies, Depression Clinical and Research Program, Massachusetts General Hospital
    Instructor in Psychiatry, Harvard Medical School
  • Director, Center for Women's Mental Health Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital
    Edmund N. and Carroll M. Carpenter Professor of Psychiatry, Harvard Medical School
    Co-Chair, Reproductive Mental Health Initiative Office of Reproductive Health/Veterans Health Administration
  • Director, Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital
    Associate Professor of Psychiatry, Harvard Medical School
  • Director, Geriatric Psychiatry Program, McLean Hospital
    Associate Professor of Psychiatry, Harvard Medical School
  • Director, Center for Addiction Medicine, Massachusetts General Hospital
    William Cox Family Associate Professor of Psychiatry in the Field of Addiction Medicine, Harvard Medical School
  • Director, Clinical Research Program (CRP)
    Executive Vice Chair, Department of Psychiatry
    Executive Director, Clinical Trials Network & Institute (CTNI)
    Massachusetts General Hospital
    Slater Family Professor of Psychiatry,
    Harvard Medical School
  • Associate Medical Director, Clinical Trials Network & Institute
    Associate Director, Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital
    Associate Professor of Psychiatry, Harvard Medical School
  • Medical Director, MGH Schizophrenia Program, Massachusetts General Hospital
    Associate Professor of Psychiatry, Harvard Medical School
  • Director, Postgraduate Medical Education, Massachusetts General Hospital
    Staff Psychiatrist, Massachusetts General Hospital
    Assistant Professor of Psychiatry, Harvard Medical School
  • Director, MGH Teen Mentor Program, Eating Disorders Clinical and Research Program, Massachusetts General Hospital
    Staff Psychiatrist, Massachusetts General Hospital
    Instructor in Psychiatry, Harvard Medical School
  • Director, Schizophrenia Clinical and Research Program
    Director, Chester M. Pierce, M.D. Division of Global Psychiatry
    Massachusetts General Hospital
    Associate Professor of Psychiatry
    Harvard Medical School
    Associate Professor of Epidemiology
    Harvard School of Public Health
  • Founder, OCD Program, Massachusetts General Hospital
    Founder and Director, OCD Institute, McLean Hospital
    Professor of Psychiatry, Harvard Medical School
  • Director of Research, Depression Clinical and Research Program, MGH
    Associate Professor of Psychiatry, Harvard Medical School
  • Director, Bipolar Clinic and Research Program, MGH
    Associate Director, Depression Clinical and Research Program, MGH
    Professor of Psychiatry, Harvard Medical School
  • Clinical Director of Psychotic Disorders Division, McLean Hospital
    Assistant Professor of Psychiatry, Harvard Medical School
  • Director, Translational Research Program at the Center for Anxiety and Related Disorders, Boston University
    Professor of Psychology, Boston University
  • Director of Treatment-Resistant Depression Studies, Department of Psychiatry, MGH
    Associate Professor of Psychiatry, Harvard Medical School
  • Medical Director, Bipolar Clinic and Research Program, Massachusetts General Hospital
    Principal Investigator, Center for Human Genetic Research, Massachusetts General Hospital
    Associate Professor of Psychiatry, Harvard Medical School
  • Associate Chief of Psychiatry, Boston VA Healthcare System
    Consultant, Department of Psychiatry, Massachusetts General Hospital
    Associate Professor of Psychiatry, Boston University School of Medicine
  • Vice President, Department of Psychiatry and Community Health Initiatives, Massachusetts General Hospital
  • Psychiatrist-in-Chief, Massachusetts General Hospital
    Stanley Cobb Professor of Psychiatry, Harvard Medical School
  • Director, Law & Psychiatry Service, Massachusetts General Hospital
    Associate Professor of Psychiatry, Harvard Medical School
  • Chief Medical Officer, Red Sox Foundation and Massachusetts General Hospital Home Base Program
    Associate Professor of Psychiatry, Harvard Medical School
    Director, Center for Anxiety & Traumatic Stress Related Disorders, Massachusetts General Hospital
  • Associate Chief of Psychiatry, Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital
    Associate Professor of Psychiatry, Harvard Medical School
  • Nursing Director, Inpatient Psychiatry, Massachusetts General Hospital
  • Associate Medical Director, Massachusetts General Physician Organization
    Department of Psychiatry, Massachusetts General Hospital
  • Associate Physician, Division of Sleep Medicine, Brigham and Women's Hospital
    Associate Professor of Psychiatry, Harvard Medical School
  • Director, Child and Adolescent Outpatient Department, Massachusetts General Hospital
    Director, Pediatric Bipolar Disorder Clinical and Research Program, Massachusetts General Hospital
    Associate Professor of Psychiatry, Harvard Medical School

Testimonials

Read some of the comments made by past attendees of our conference:

"Updated information certainly helps my treatment decisions. It is why this course is so important to me."

"I attend this conference yearly. This keeps me working at my optimum."

"Every time I find content that helps me with my daily clinical work."

"I have been attending this program…for the last 20 years. Every time I take away at least a few new ideas and pearls."

"This seminar has improved my confidence in handling non-routine situations."

"This conference provides new tools for treating refractory patients."

"As someone who supervises a prescribing nurse, this material is invaluable in helping me to keep up."

"This conference always presents attendees with analyses of evidence-based data and recommendations for treatment."

"I will follow new algorithms for treatment of bipolar disorder, major depression and schizophrenia in my practice."

Translate Knowledge Into Practice

Our conference lets you engage dozens of renowned clinician-researchers, get your clinical questions answered, and translate enhanced knowledge into optimal patient care.

Read some of the ways that participants plan to change their clinical practice as a result of attending our conference:

  • Focus on reducing side effects of medication
  • Apply newer strategies in treatment of chemical abuse/dependence
  • Explain more succinctly why to choose a particular medication for a person
  • Explain more clearly how medications affect behaviors and mood
  • Use more evidence-based treatment for psychiatric illness
  • Move to augmentation strategies sooner
  • Screen patients for presence of substance use disorders, especially nicotine and alcohol
  • Renew a collaborative relationship with specialists to begin assisting in performing medication renewals
  • Include newly researched alternatives for augmentation treatment in refractory patients
  • More confidently weigh risks and benefits of treating vs. not continuing treatment during pregnancy
  • Be more cautious associating medications
  • Improve ability to convey to patients the range of treatment options
  • Better evaluate whether medication is needed and consider alternative treatments
  • Institute adjunctive medications that were not thought of previously
  • Follow new algorithms for treatment of bipolar disorder, major depression and schizophrenia
  • Integrate more augmentation strategies and increase use of maintenance ECT
  • Inform patients and colleagues of the most recent state-of-the-art alternatives
  • Take a more substantial sleep history
  • Consider problems that are causing difficulties with cognition, mood, and anxiety
  • Try natural remedies for treatment of depression
  • Educate patients more thoroughly with recent study results
  • Provide patients with more focused and comprehensive discussions regarding and symptom complexes
  • Be more knowledgeable and complete when referring patients
  • Develop a plan to use CBT based techniques
  • Change approaches related to maintenance treatment of bipolar disorder and treatment of mood disorders during pregnancy
  • Thoroughly discuss with patients how current available treatments work and increase medication adherence

CME Information

Live Event Date: October 24, 2014 – October 26, 2014 

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

McLean Hospital designates this live activity for a maximum of 26.75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Designation

Psychologists: The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for 26.75 Continuing Education (CE) credit per presentation for psychologists.

Nurses: This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 26.75 contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

Social Workers: This program has been approved for 25.00 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 70006.

Other Professions: Other Providers can claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 CreditsTM associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 CreditsTM may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.


Policy on Faculty and Provider Disclosure

It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. McLean Hospital has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.

Resolution of Conflict of Interest (COI)

McLean Hospital has implemented a process to resolve COI for each CME activity. In order to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public, McLean Hospital has resolved the conflict by External Content Review.


Planner Disclosures

The following planners and/or their spouse/partner have reported no relevant financial relationship with a commercial interest.

Tristan Gorrindo, MD
Jane Pimental, MPH

The following planners and/or their spouse/partner have reported a relevant financial relationship with a commercial interest.

Maurizio Fava, MD
Research Support: Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Clintara, LLC; Covance; Covidien; Eli Lilly and Company;EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; MedAvante;  National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals;  PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.;  Pharmavite® LLC;PharmoRx Therapeutics;  Photothera; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC;  Shire; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories

Advisory/Consulting: Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor;Clinical Trials Solutions;  CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLCKnoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG;Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures;  PsychoGenics; Psylin Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.

Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/PrimediaMGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst Laboratories

Equity Holdings: Compellis; PsyBrain, Inc.

Royalty/patent, other income:
Patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to RCT Logic, LLC; and patent application for a combination of Scopolamine and Ketamine in Major Depressive Disorder (MDD)
Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd.

Jerrold F. Rosenbaum, MD
Equity interest: MedAvante
Equity interest; Board of Directors: PsyBrain


Hardware/Software Specifications

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration

Flash Player: Adobe Flash Player 10.1+ 
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
Operating System: Windows XP+ or Mac OS X 10.4+ 
Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera 
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit


Privacy Policy

Please click here to review our privacy policy.

Location

10 Huntington Avenue, The Westin Copley Place, Boston, MA, USA